DE69830582T2 - Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind - Google Patents

Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind Download PDF

Info

Publication number
DE69830582T2
DE69830582T2 DE69830582T DE69830582T DE69830582T2 DE 69830582 T2 DE69830582 T2 DE 69830582T2 DE 69830582 T DE69830582 T DE 69830582T DE 69830582 T DE69830582 T DE 69830582T DE 69830582 T2 DE69830582 T2 DE 69830582T2
Authority
DE
Germany
Prior art keywords
lactoferrin
tnf
treatment
dendritic cells
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830582T
Other languages
German (de)
English (en)
Other versions
DE69830582D1 (de
Inventor
Ian Knutsford KIMBER
Marie Wilmslow CUMBERBATCH
J. Rebecca Macclesfield DEARMAN
M. Orla CONNEELY
Pauline Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Application granted granted Critical
Publication of DE69830582D1 publication Critical patent/DE69830582D1/de
Publication of DE69830582T2 publication Critical patent/DE69830582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69830582T 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind Expired - Lifetime DE69830582T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
US41890P 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (2)

Publication Number Publication Date
DE69830582D1 DE69830582D1 (de) 2005-07-21
DE69830582T2 true DE69830582T2 (de) 2006-05-04

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830582T Expired - Lifetime DE69830582T2 (de) 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Country Status (12)

Country Link
US (1) US20030190303A1 (enExample)
EP (1) EP0979099B1 (enExample)
JP (1) JP2001519815A (enExample)
CN (1) CN1262625A (enExample)
AT (1) ATE297755T1 (enExample)
AU (1) AU747385C (enExample)
CA (1) CA2285960A1 (enExample)
DE (1) DE69830582T2 (enExample)
ES (1) ES2245028T3 (enExample)
IL (1) IL132293A0 (enExample)
NZ (1) NZ500712A (enExample)
WO (1) WO1998044940A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050076A1 (en) * 1997-05-03 1998-11-12 Board Of Regents, The University Of Texas System Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN100384472C (zh) * 2000-01-14 2008-04-30 明治乳业株式会社 抗原特异性IgE抗体产生抑制剂
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
JP3806427B2 (ja) * 2002-01-21 2006-08-09 株式会社Ｎｒｌファーマ 新規鎮痛剤
AU2003273182B8 (en) * 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2003099207A2 (en) 2002-05-24 2003-12-04 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
DE60335997D1 (de) * 2002-09-16 2011-03-24 Agennix Inc Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
US20040152624A1 (en) * 2002-12-06 2004-08-05 Atul Varadhachary Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
US20090203586A1 (en) * 2004-06-11 2009-08-13 Syngenta Limited Method for ameliorating an inflammatory skin condition
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
WO2006098625A1 (en) 2005-03-15 2006-09-21 Campina Nederland Holding B.V. Dermatologic use of milk proteins
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
AU2006300009A1 (en) * 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
EP1952818A4 (en) * 2005-10-27 2009-10-21 Sunstar Inc OSTEOCLASTICIZATION PREPARATION, ORAL AGGREGATION AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST BONE DISEASES WITH LACTOFERRIN-CONTAINING LIPOSOME
EP2560679A4 (en) * 2010-04-23 2013-09-18 Probiotec Ltd TREATMENT OF ECZEMA
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
PL4072322T3 (pl) * 2019-12-11 2025-05-19 N.V. Nutricia Kompozycja do żywienia do poprawy sprawności układu odpornościowego
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
CN1262625A (zh) 2000-08-09
AU747385B2 (en) 2002-05-16
EP0979099A1 (en) 2000-02-16
IL132293A0 (en) 2001-03-19
WO1998044940A1 (en) 1998-10-15
AU747385C (en) 2003-01-30
ATE297755T1 (de) 2005-07-15
ES2245028T3 (es) 2005-12-16
NZ500712A (en) 2002-10-25
CA2285960A1 (en) 1998-10-15
JP2001519815A (ja) 2001-10-23
DE69830582D1 (de) 2005-07-21
US20030190303A1 (en) 2003-10-09
EP0979099B1 (en) 2005-06-15
AU6964798A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE3689909T2 (de) Verwendung eines GHL-Cu enthaltenden Stoffes zur Herstellung eines Arzneimittels für Wunden.
DE10234192B4 (de) Verwendung von Erythropoetin
DE69828614T2 (de) Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6
DE3855970T2 (de) Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus
DE69736712T2 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
DE69419907T2 (de) Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege
DE69228700T2 (de) Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
DE69907577T2 (de) Entzündungshemmende Zusammensetzung
EP0149468A2 (de) Biologisch wirksame Substanz mit hormonellen Eigenschaften, Verfahren zu ihrer Herstellung und Verwendung von Histonen für medizinische Zwecke
DE69007964T2 (de) Verwendung von Thrombospondin zur Beschleunigung der Wundheilung.
DE60207043T2 (de) Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese
DE69902127T2 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
DE69835832T2 (de) Zusammensetzungen und methoden zur regulierung der phagozytose und icam-1 expression
DE60128399T2 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
DE69725897T2 (de) Behandlung von störungen mittels interleukin-9
DE69527145T2 (de) Verfahren zur behandlung von blutungsstorungen
EP2227246B1 (de) Behandlung von fibrosen und lebererkrankungen
DE69728654T2 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69431430T2 (de) Faktor XIII zur Behandlung von Hautwunden
DE69620888T2 (de) Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
WO1998019160A2 (de) VERFAHREN ZUR INDIREKTEN BESTIMMUNG DER TYP I INTERFERON-PRODUKTION IN VIVO MITTELS ANTIKÖRPER GEGEN HUMANE Mx-PROTEINE SOWIE ANTIKÖRPER HIERZU
DE69417872T2 (de) Inhibitor peptid spezifisch für cathepsin-l
DE60031132T2 (de) Zusammensetzungen zur eröffnung der wasserkanäle und medizinische zusammensetzungen zur opthalmischer verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition